Peptide receptor radionuclide therapy (PRRT) now plays a critical role in the treatment of patients with advanced neuroendocrine neoplasms (NENs). The landmark NETTER-1 and NETTER-2 trials demonstrated significant improvements in progression-free survival compared with somatostatin analog treatment
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: